Last Updated : July 15, 2024
Details
Generic Name:
pembrolizumab
Project Status:
Received
Therapeutic Area:
Non-small cell lung cancer (NSCLC)
Manufacturer:
Merck Canada
Call for patient/clinician input open:
Brand Name:
Keytruda
Project Line:
Reimbursement Review
Project Number:
PC0369-000
Call for patient/clinician input closed:
Tumour Type:
Lung
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Keytruda as monotherapy for the adjuvant treatment of adult patients with Stage IB (T2a 4 cm), II, or IIIA NSCLC, and with PD-L1 tumor proportion score (TPS) 50% who have undergone complete resection and platinum-based chemotherapy.
Submission Type:
Initial
Companion Diagnostics:
Yes
Fee Schedule:
Pending
Indications:
Keytruda as monotherapy is indicated for the adjuvant treatment of adult patients with Stage IB (T2a ≥ 4 cm), II, or IIIA NSCLC who have undergone complete resection and platinum-based chemotherapy.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | 03-Jun-24 |
|---|---|
| Call for patient/clinician input closed | 26-Jul-24 |
| Submission received | 15-Jul-24 |
| Submission accepted | - |
Last Updated : July 15, 2024